Top

World Journal of Urology

Published in:

01-12-2024 | Benign Prostatic Hypertrophy | Original Article

Association between chronic prostatitis and the subsequent benign prostatic hyperplasia: a population-based national cohort study

Authors: Tsung-Yen Lin, I-Hung Chen, Han-Yu Weng, Yu-Chiao Lin, Chien-Hui Ou, Chung-Yi Li, Yu-Sheng Cheng

Published in: World Journal of Urology | Issue 1/2024

Abstract

Purpose

To explore the association between chronic prostatitis (CP) and the subsequent development of benign prostatic hyperplasia (BPH).

Methods

Data analyzed were medical claims of Taiwan’s National Health Insurance program. From 2010 to 2017, 3571 patients ≧20 years with CP diagnosed by certified urologists were enrolled. Patients with past BPH diagnosis and diagnosis of prostate cancer, inguinal hernia, interstitial cystitis, and urethritis in the past and within one year after the first CP diagnosis were excluded. Age-matched controls were randomly selected from all non-CP individuals of the same exclusion criteria in the study period with a CP/non-CP ratio of 1:4. The follow-up was made from the first CP diagnosis to death or the end of 2018. The endpoint was the newly diagnosed BPH. Cox proportional hazard regression model was used to estimate the hazard ratio (HR) and 95% confidence interval (CI) of BPH in association with CP.

Results

Over a maximum of 8 years of follow-up, 287 (8.03%) and 258 (0.43%) BPH events were noted for the CP and non-CP group, respectively, representing a covariate adjusted HR (aHR) of 4.30 (95% CI, 3.61–5.13). Younger patients tended to suffer from higher aHRs, especially those aged 20–39 years (aHR: 11.45, 95% CI, 5.12–25.64).

Conclusion

The Taiwan national health database indicated that CP patients had a significantly higher risk of developing BPH later than non-CP patients. Interestingly, the younger the CP is diagnosed (under 40), the greater the risk.

Available only for authorised users

Krieger JN, Lee SW, Jeon J et al (2008) Epidemiology of prostatitis. Int J Antimicrob Agents 31(Suppl 1):S85. https://doi.org/10.1016/j.ijantimicag.2007.08.028CrossRefPubMed

Khan FU, Ihsan AU, Khan HU et al (2017) Comprehensive overview of prostatitis. Biomed Pharmacother 94:1064–1076. https://doi.org/10.1016/j.biopha.2017.08.016CrossRefPubMed

Collins MM, Stafford RS, O’Leary MP et al (1998) How common is prostatitis? A national survey of physician visits. J Urol 159:1224–1228. https://doi.org/10.1016/S0022-5347(01)63564-XCrossRefPubMed

Litwin MS, McNaughton-Collins M, Fowler FJ Jr et al (1999) The National Institutes of Health chronic prostatitis symptom index: development and validation of a new outcome measure. Chronic Prostatitis Collaborative Research Network. J Urol 162:369–375. https://doi.org/10.1016/s0022-5347(05)68562-xCrossRefPubMed

Roberts RO, Lieber MM, Rhodes T et al (1998) Prevalence of a physician-assigned diagnosis of prostatitis: the Olmsted County Study of Urinary Symptoms and Health Status Among Men. Urology 51:578–584. https://doi.org/10.1016/S0090-4295(98)00034-XCrossRefPubMed

Liang CZ, Zhang XJ, Hao ZY et al (2004) An epidemiological study of patients with chronic prostatitis. BJU Int 94:568–570. https://doi.org/10.1111/j.1464-410X.2004.05002.xCrossRefPubMed

Lee SWH, Chan EMC, Lai YK (2017) The global burden of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systematic review and meta-analysis. Sci Rep 7:7984. https://doi.org/10.1038/s41598-017-06628-8ADSCrossRefPubMedPubMedCentral

Xu XF, Liu GX, Guo YS et al (2021) Global, regional, and national incidence and year lived with disability for benign prostatic hyperplasia from 1990 to 2019. Am J Mens Health 15:15579883211036786. https://doi.org/10.1177/15579883211036786CrossRefPubMedPubMedCentral

Madersbacher S, Sampson N, Culig Z (2019) Pathophysiology of benign prostatic hyperplasia and benign prostatic enlargement: a mini-review. Gerontology 65:458–464. https://doi.org/10.1159/000496289CrossRefPubMed

10.

Gandaglia G, Briganti A, Gontero P et al (2013) The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH). BJU Int 112:432–441. https://doi.org/10.1111/bju.12118CrossRefPubMed

11.

De Nunzio C, Presicce F, Tubaro A (2016) Inflammatory mediators in the development and progression of benign prostatic hyperplasia. Nat Rev Urol 13:613–626. https://doi.org/10.1038/nrurol.2016.168CrossRefPubMed

12.

Ning X, Shi JP, Wu ZY et al (2003) A case-control study on the risk factors of benign prostatic hyperplasia in the suburb of Shenyang; article in Chinese. Zhonghua Liu Xing Bing Xue Za Zhi 24:276–280. https://rs.yiigle.com/cmaid/678920

13.

St Sauver JL, Jacobson DJ, McGree ME et al (2008) Longitudinal association between prostatitis and development of benign prostatic hyperplasia. Urology 71:475–479. https://doi.org/10.1016/j.urology.2007.11.155CrossRefPubMed

14.

Calogero AE, Burgio G, Condorelli RA et al (2019) Epidemiology and risk factors of lower urinary tract symptoms/benign prostatic hyperplasia and erectile dysfunction. Aging Male 22:12–19. https://doi.org/10.1080/13685538.2018.1434772CrossRefPubMed

15.

Safarinejad MR (2008) Prevalence of benign prostatic hyperplasia in a population-based study in Iranian men 40 years old or older. Int Urol Nephrol 40:921–931. https://doi.org/10.1007/s11255-008-9338-7CrossRefPubMed

16.

Koh JS, Ko HJ, Wang SM et al (2015) The Relationship between depression, anxiety, somatization, personality and symptoms of lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Psychiatry Investig 12:268–273. https://doi.org/10.4306/pi.2015.12.2.268CrossRefPubMed

17.

Peng YH, Huang CW, Liao WC et al (2017) Association between chronic obstructive pulmonary disease and increased risk of benign prostatic hyperplasia: a retrospective nationwide cohort study. BMJ Open 7:e015581. https://doi.org/10.1136/bmjopen-2016-015581CrossRefPubMedPubMedCentral

18.

Li WM, Pasaribu N, Lee SS et al (2018) Risk of incident benign prostatic hyperplasia in patients with gout: a retrospective cohort study. Prostate Cancer Prostatic Dis 21:277–286. https://doi.org/10.1038/s41391-018-0047-8CrossRefPubMed

19.

Peng YH, Huang CW, Chou CY et al (2020) Association between asthma and risk of benign prostatic hyperplasia: a retrospective population-based study. Aging Male 23:599–606. https://doi.org/10.1080/13685538.2018.1552253CrossRefPubMed

20.

Huang JF, Shen N, Zhao JM et al (2023) Relationship between severity of obstructive sleep apnea and benign prostatic hyperplasia. Sleep Breath 27:363–369. https://doi.org/10.1007/s11325-022-02617-yCrossRefPubMed

21.

Feghali CA, Wright TM (1997) Cytokines in acute and chronic inflammation. Front Biosci 2:d12-26. https://doi.org/10.2741/a171CrossRefPubMed

22.

Berry SJ, Coffey DS, Walsh PC et al (1984) The development of human benign prostatic hyperplasia with age. J Urol 132:474–479. https://doi.org/10.1016/s0022-5347(17)49698-4CrossRefPubMed

23.

Maserejian NN, Chen S, Chiu GR et al (2013) Incidence of lower urinary tract symptoms in a population-based study of men and women. Urology 82:560–564. https://doi.org/10.1016/j.urology.2013.05.009CrossRefPubMed

24.

Toh KL, Ng CK (2006) Urodynamic studies in the evaluation of young men presenting with lower urinary tract symptoms. Int J Urol 13:520–523. https://doi.org/10.1111/j.1442-2042.2006.01347.xCrossRefPubMed

25.

Chiancone F, Carrino M, Meccariello C et al (2019) The use of a combination of vaccinium macracarpon, Lycium barbarum L. and Probiotics (Bifiprost®) for the prevention of chronic bacterial prostatitis: a double-blind randomized study. Urol Int 103:423–426. https://doi.org/10.1159/000502765CrossRefPubMed

26.

Cai T, Gallelli L, Cione E et al (2021) The use of Lactobacillus casei DG® prevents symptomatic episodes and reduces the antibiotic use in patients affected by chronic bacterial prostatitis: results from a phase IV study. World J Urol 39:3433–3440. https://doi.org/10.1007/s00345-020-03580-7CrossRefPubMedPubMedCentral

27.

Zhang R, Chomistek AK, Dimitrakoff JD et al (2015) Physical activity and chronic prostatitis/chronic pelvic pain syndrome. Med Sci Sports Exerc 47:757–764. https://doi.org/10.1249/MSS.0000000000000472CrossRefPubMedPubMedCentral

28.

Gacci M, Sebastianelli A, Salvi M et al (2017) Benign prostatic enlargement can be influenced by metabolic profile: results of a multicenter prospective study. BMC Urol 17:22. https://doi.org/10.1186/s12894-017-0211-9CrossRefPubMedPubMedCentral

29.

Shih HJ, Tsai PS, Wen YC et al (2020) Hyperlipidemia patients with long-term statin treatment are associated with a reduced risk of progression of benign prostatic enlargement. Aging Male 23:354–361. https://doi.org/10.1080/13685538.2018.1487392CrossRefPubMed

30.

Vignozzi L, Gacci M, Cellai I et al (2013) Fat boosts, while androgen receptor activation counteracts, BPH-associated prostate inflammation. Prostate 73:789–800. https://doi.org/10.1002/pros.22623CrossRefPubMed

Title: Association between chronic prostatitis and the subsequent benign prostatic hyperplasia: a population-based national cohort study
Authors: Tsung-Yen Lin
I-Hung Chen
Han-Yu Weng
Yu-Chiao Lin
Chien-Hui Ou
Chung-Yi Li
Yu-Sheng Cheng
Publication date: 01-12-2024
Publisher: Springer Berlin Heidelberg
Keywords: Benign Prostatic Hypertrophy
Benign Prostatic Hypertrophy
Prostatitis
Published in: World Journal of Urology / Issue 1/2024
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-024-04820-w

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Association between chronic prostatitis and the subsequent benign prostatic hyperplasia: a population-based national cohort study

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2024

Genetic susceptibility of urolithiasis: comprehensive results from genome-wide analysis

The association between patient and disease characteristics, and the risk of disease progression in patients with prostate cancer on active surveillance

Comparisons of mpMRI, 68Ga-PSMA PET/CT and mpMRI combined with 68Ga-PSMA PET/CT in diagnosing prostate cancer based on tumor detection, localization and staging

MR defecography in assessing stress urinary incontinence with or without symptomatic pelvic organ prolapse

Unveiling the challenges of UTUC biopsies and cytology: insights from a global real-world practice study

A new protocol to reduce postoperative infections for retrograde intrarenal surgery: irrigating antibiotic in renal collecting system